BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/20/2023 4:48:38 PM | Browse: 99 | Download: 153
 |
Received |
|
2023-07-26 06:43 |
|
Peer-Review Started |
|
2023-07-26 06:47 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-08-16 05:39 |
|
Revised |
|
2023-08-24 22:50 |
|
Second Decision |
|
2023-08-31 07:05 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-08-31 08:02 |
|
Articles in Press |
|
2023-08-31 08:02 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-09-09 15:38 |
|
Publish the Manuscript Online |
|
2023-09-20 16:48 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Otorhinolaryngology |
| Manuscript Type |
Case Report |
| Article Title |
Complete response of metastatic BRAF V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sang Jae Lee, Si-Youn Song, Min Kyoung Kim, Hyung Gyun Na, Chang Hoon Bae, Yong-Dae Kim and Yoon Seok Choi |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| 2023 Yeungnam University Research Grant |
|
|
| Corresponding Author |
Yoon Seok Choi, MD, PhD, Associate Professor, Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Yeungnam University, 170, Hyeonchung-ro, Nam-Gu, Daegu 42415, South Korea. choiys@ynu.ac.kr |
| Key Words |
Thyroid carcinoma; Anaplastic; BRAF; Dabrafenib; Trametinib; Chemotherapy; Adjuvant; Case report |
| Core Tip |
Anaplastic thyroid cancer (ATC) is a rare but aggressive type of thyroid carcinoma. The BRAF V600E-mutation, found in 10%-50% of ATCs, is associated with a poor prognosis. A recent clinical trial reported a substantial clinical benefit of dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in treating BRAF V600E-mutant ATC. This report highlights the therapeutic potential of dabrafenib plus trametinib as an adjuvant chemotherapy to treat and prevent the recurrence of ATC confirmed with BRAF mutation following surgical resection. |
| Publish Date |
2023-09-20 16:48 |
| Citation |
Lee SJ, Song SY, Kim MK, Na HG, Bae CH, Kim YD, Choi YS. Complete response of metastatic BRAF V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report. World J Clin Cases 2023; 11(27): 6664-6669 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i27/6664.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i27.6664 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
